Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Growth 2022-2028
The global market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key SGLT-2 Inhibitors for Type 2 Diabetes Treatment players cover AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Merck and Sanofi, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, with both quantitative and qualitative data, to help readers understand how the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in M Units.
Market Segmentation:
The study segments the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market and forecasts the market size by Type (Empagliflozin, Dapagliflozin and Canagliflozin), by Application (Offline Retail Pharmacy, Hospitals and Clinics and E-commerce and Internet Medical Care,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Empagliflozin
Dapagliflozin
Canagliflozin
Others
Segmentation by application
Offline Retail Pharmacy
Hospitals and Clinics
E-commerce and Internet Medical Care
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
AstraZeneca
Johnson & Johnson
Boehringer Ingelheim
Merck
Sanofi
Astellas
Chugai Pharmaceutical
Taisho Pharmaceutical
Jiangsu Hengrui Medicine
Chapter Introduction
Chapter 1: Scope of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Research Methodology, etc.
Chapter 2: Executive Summary, global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size (sales and revenue) and CAGR, SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Merck, Sanofi, Astellas, Chugai Pharmaceutical, Taisho Pharmaceutical and Jiangsu Hengrui Medicine, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Country/Region, 2017, 2022 & 2028
2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type
2.2.1 Empagliflozin
2.2.2 Dapagliflozin
2.2.3 Canagliflozin
2.2.4 Others
2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
2.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
2.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue and Market Share by Type (2017-2022)
2.3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Type (2017-2022)
2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application
2.4.1 Offline Retail Pharmacy
2.4.2 Hospitals and Clinics
2.4.3 E-commerce and Internet Medical Care
2.5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
2.5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Market Share by Application (2017-2022)
2.5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue and Market Share by Application (2017-2022)
2.5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Application (2017-2022)
3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Company
3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Breakdown Data by Company
3.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Company (2020-2022)
3.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Company (2020-2022)
3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Company (2020-2022)
3.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2020-2022)
3.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2020-2022)
3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Company
3.4 Key Manufacturers SGLT-2 Inhibitors for Type 2 Diabetes Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Location Distribution
3.4.2 Players SGLT-2 Inhibitors for Type 2 Diabetes Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Geographic Region
4.1 World Historic SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Geographic Region (2017-2022)
4.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Geographic Region (2017-2022)
4.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Geographic Region
4.2 World Historic SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country/Region (2017-2022)
4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Country/Region (2017-2022)
4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Country/Region
4.3 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.4 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.5 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.6 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth
5 Americas
5.1 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
5.1.1 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
5.1.2 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
5.2 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
5.3 Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region
6.1.1 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2017-2022)
6.1.2 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2017-2022)
6.2 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
6.3 APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Country
7.1.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
7.1.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
7.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
7.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Country
8.1.1 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
8.1.2 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
8.2 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
8.3 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
10.3 Manufacturing Process Analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
10.4 Industry Chain Structure of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
11.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customer
12 World Forecast Review for SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Geographic Region
12.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Region
12.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecast by Region (2023-2028)
12.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecast by Type
12.7 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.1.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.2.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Information
13.3.2 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.3.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Boehringer Ingelheim Main Business Overview
13.3.5 Boehringer Ingelheim Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.4.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.5.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Astellas
13.6.1 Astellas Company Information
13.6.2 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.6.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Astellas Main Business Overview
13.6.5 Astellas Latest Developments
13.7 Chugai Pharmaceutical
13.7.1 Chugai Pharmaceutical Company Information
13.7.2 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.7.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Chugai Pharmaceutical Main Business Overview
13.7.5 Chugai Pharmaceutical Latest Developments
13.8 Taisho Pharmaceutical
13.8.1 Taisho Pharmaceutical Company Information
13.8.2 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.8.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Taisho Pharmaceutical Main Business Overview
13.8.5 Taisho Pharmaceutical Latest Developments
13.9 Jiangsu Hengrui Medicine
13.9.1 Jiangsu Hengrui Medicine Company Information
13.9.2 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.9.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Jiangsu Hengrui Medicine Main Business Overview
13.9.5 Jiangsu Hengrui Medicine Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Empagliflozin
Table 4. Major Players of Dapagliflozin
Table 5. Major Players of Canagliflozin
Table 6. Major Players of Others
Table 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2017-2022) & ($ million)
Table 10. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2017-2022)
Table 11. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Type (2017-2022) & (US$/K Unit)
Table 12. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2017-2022)
Table 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2017-2022)
Table 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Application (2017-2022) & (US$/K Unit)
Table 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Company (2020-2022) & (M Units)
Table 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Company (2020-2022)
Table 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2020-2022) ($ Millions)
Table 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2020-2022)
Table 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sale Price by Company (2020-2022) & (US$/K Unit)
Table 22. Key Manufacturers SGLT-2 Inhibitors for Type 2 Diabetes Treatment Producing Area Distribution and Sales Area
Table 23. Players SGLT-2 Inhibitors for Type 2 Diabetes Treatment Products Offered
Table 24. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Geographic Region (2017-2022) & (M Units)
Table 28. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Geographic Region (2017-2022)
Table 29. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country/Region (2017-2022) & (M Units)
Table 32. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country/Region (2017-2022)
Table 33. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 36. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 37. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 39. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 40. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 41. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 42. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 43. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2017-2022) & (M Units)
Table 44. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2017-2022)
Table 45. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2017-2022)
Table 47. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 48. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 49. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 50. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 51. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 52. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 53. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 55. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 56. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 57. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 58. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 60. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 64. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 66. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Table 68. Key Market Challenges & Risks of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Table 69. Key Industry Trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Table 70. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List
Table 73. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customer List
Table 74. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Region (2023-2028) & (M Units)
Table 75. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Forecast by Region
Table 76. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 79. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Region (2023-2028) & (M Units)
Table 81. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 83. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 85. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Type (2023-2028) & (M Units)
Table 87. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Type (2023-2028)
Table 88. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Application (2023-2028) & (M Units)
Table 91. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Application (2023-2028)
Table 92. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 94. AstraZeneca Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 96. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 97. AstraZeneca Main Business
Table 98. AstraZeneca Latest Developments
Table 99. Johnson & Johnson Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 101. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 102. Johnson & Johnson Main Business
Table 103. Johnson & Johnson Latest Developments
Table 104. Boehringer Ingelheim Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 106. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 107. Boehringer Ingelheim Main Business
Table 108. Boehringer Ingelheim Latest Developments
Table 109. Merck Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 111. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 112. Merck Main Business
Table 113. Merck Latest Developments
Table 114. Sanofi Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 116. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 117. Sanofi Main Business
Table 118. Sanofi Latest Developments
Table 119. Astellas Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 121. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 122. Astellas Main Business
Table 123. Astellas Latest Developments
Table 124. Chugai Pharmaceutical Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 126. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 127. Chugai Pharmaceutical Main Business
Table 128. Chugai Pharmaceutical Latest Developments
Table 129. Taisho Pharmaceutical Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 130. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 131. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 132. Taisho Pharmaceutical Main Business
Table 133. Taisho Pharmaceutical Latest Developments
Table 134. Jiangsu Hengrui Medicine Basic Information, SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 135. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 136. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 137. Jiangsu Hengrui Medicine Main Business
Table 138. Jiangsu Hengrui Medicine Latest Developments
List of Figures
Figure 1. Picture of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Figure 2. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate 2017-2028 (M Units)
Figure 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Empagliflozin
Figure 10. Product Picture of Dapagliflozin
Figure 11. Product Picture of Canagliflozin
Figure 12. Product Picture of Others
Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type in 2021
Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2017-2022)
Figure 15. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Consumed in Offline Retail Pharmacy
Figure 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market: Offline Retail Pharmacy (2017-2022) & (M Units)
Figure 17. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Consumed in Hospitals and Clinics
Figure 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market: Hospitals and Clinics (2017-2022) & (M Units)
Figure 19. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Consumed in E-commerce and Internet Medical Care
Figure 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market: E-commerce and Internet Medical Care (2017-2022) & (M Units)
Figure 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Figure 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application in 2021
Figure 23. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market by Company in 2021 ($ Million)
Figure 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company in 2021
Figure 25. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Geographic Region in 2021
Figure 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2017-2022)
Figure 28. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country/Region in 2021
Figure 29. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 30. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 31. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 32. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 33. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 34. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 36. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 37. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 38. Americas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 39. United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region in 2021
Figure 44. APAC SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Regions in 2021
Figure 45. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 49. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 52. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 53. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 54. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 59. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 60. Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in 2021
Figure 66. Manufacturing Process Analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Figure 67. Industry Chain Structure of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets